APA (7th ed.) Citation

ZA, W., JM, L., A, P., S, Z., M, S., M, H., . . . TR, D. (2026). Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: A pilot phase 1 trial. Nature communications, 17(1), . https://doi.org/10.1038/s41467-026-68976-2

Chicago Style (17th ed.) Citation

ZA, Wainberg, et al. "Neoadjuvant Modified FOLFIRINOX Plus Nivolumab in Borderline-resectable Pancreatic Ductal Adenocarcinoma: A Pilot Phase 1 Trial." Nature Communications 17, no. 1 (2026). https://doi.org/10.1038/s41467-026-68976-2.

MLA (9th ed.) Citation

ZA, Wainberg, et al. "Neoadjuvant Modified FOLFIRINOX Plus Nivolumab in Borderline-resectable Pancreatic Ductal Adenocarcinoma: A Pilot Phase 1 Trial." Nature Communications, vol. 17, no. 1, 2026, https://doi.org/10.1038/s41467-026-68976-2.